Vital-Medicina Kft.

The trials here

What the 34 trials at this site are about, from their registry records.

Conditions

• Psoriatic arthritis14 trials
• Psoriasis10 trials
• Rheumatoid arthritis10 trials
• Lupus (SLE)4 trials
• Ankylosing spondylitis2 trials
• Osteoarthritis2 trials
• Polymyalgia rheumatica2 trials
• Giant cell arteritis1 trial

Phase

• Phase 321 trials
• Phase 29 trials
• Phase 43 trials
• Phase 2/31 trial

Status

• Active, not recruiting15 trials
• Completed12 trials
• Recruiting4 trials
• Not yet recruiting1 trial
• Suspended1 trial
• Withdrawn1 trial

Lead sponsor

• Janssen Research & Development, LLC7 trials
• AbbVie6 trials
• Novartis Pharmaceuticals4 trials
• MoonLake Immunotherapeutics AG3 trials
• Takeda2 trials
• and 12 more

Running trials

• Recruiting

  A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.

  2025-522076-85-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  International study to compare the efficacy and safety of chondroitin sulfate 800 mg tablets of two different origins (bovine versus marine) in the treatment of knee osteoarthritis

  2024-516337-12-00· Phase 3· IBSA Institut Biochimique SA· Source

• Active, not recruiting

  A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis

  2024-519291-11-00· Phase 2· AbbVie Deutschland GmbH & Co. KG· Source

• Recruiting

  A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

  NCT06972446· Phase 2· AbbVie· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.

  2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Phase 3· Takeda· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

  NCT06878404· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

  NCT06754462· Phase 2· Immunovant Sciences GmbH· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

  NCT06807424· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

  NCT06331312· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

  NCT05843643· Phase 3· AbbVie· Source

• Active, not recruiting

  Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2)

  2022-500700-22-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

  NCT05622708· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

  NCT04908189· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

  NCT03671148· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

  NCT02629159· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Psoriatic arthritis3 recruiting
• Lupus (SLE)1 recruiting
• Psoriasis1 recruiting
• Rheumatoid arthritis1 recruiting

Closed trials

• Completed

  A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis

  2024-510826-16-00· Phase 3· Mabxience Research S.L.· Source

• Completed

  A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis

  2023-506664-14-00· Phase 3· Dr Reddy's Laboratories Limited· Source

• Completed

  A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

  NCT06028438· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

  NCT05856448· Phase 2· Lakefront Biotherapeutics NV· Source

• Completed

  Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· Phase 3· AbbVie· Source

• Completed

  A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is

  2022-501362-22-00· Phase 2/3· Acelyrin Inc.· Source

• Completed

  A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis

  2022-501425-20-00· Phase 2· Eli Lilly & Co.· Source

• Completed

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

  NCT05767034· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

  NCT04936308· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

  NCT04886258· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

  NCT04169373· Phase 3· AbbVie· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source